Stock market today: S&P 500 hits fresh record close on stronger economic growth
On Friday, Eli Lilly and Company (NYSE:LLY), a pharmaceutical giant with a market capitalization of $732.66 billion, maintained their Overweight rating and a $975.00 price target from analysts at Cantor Fitzgerald. The rating affirmation came despite recent market fluctuations following a new agreement between CVS Health (NYSE:CVS) and Novo Nordisk (NYSE:NVO), which triggered a significant 10.22% decline in Eli Lilly’s stock price over the past week. According to InvestingPro data, analyst targets for the stock range from $650 to $1,190, reflecting diverse market opinions about the company’s prospects.
Eli Lilly recently experienced a stock price pullback after CVS Health’s arrangement regarding Wegovy, a competing product, was announced. This agreement was perceived to overshadow Eli Lilly’s first-quarter earnings, which were slightly better than anticipated. The pharmaceutical company’s stock had previously seen an uptick following positive data from its orforglipron ACHIEVE-1 study. InvestingPro analysis shows the company maintains an impressive 81.31% gross profit margin and has achieved 32% revenue growth in the last twelve months, demonstrating strong operational performance despite market challenges.
Cantor Fitzgerald acknowledged the concerns investors might have regarding Novo Nordisk’s potential competitive strategies, which could include more aggressive commercial actions or pricing adjustments. However, the firm expressed the view that the substantial decline in Eli Lilly’s share value was not entirely justified by the company’s fundamental performance, especially in the short term.
The analyst from Cantor Fitzgerald, Carter Gould, provided insight into the situation, stating, "We think the magnitude of the move in LLY shares seems disconnected from the underlying fundamentals, particularly in the near term." This comment highlighted a belief that the market reaction might not fully align with Eli Lilly’s business outlook.
Eli Lilly’s recent financial results and the promising data from its orforglipron ACHIEVE-1 study contributed to the positive rating from Cantor Fitzgerald. Despite the competitive pressures from agreements like the one between CVS Health and Novo Nordisk, the firm’s analysts seem confident in Eli Lilly’s market position and its ability to sustain growth moving forward.
In other recent news, Eli Lilly reported a 45% increase in revenue for the first quarter of 2025, driven by strong sales of key products. However, the company’s earnings per share (EPS) fell short of expectations, coming in at $3.34 compared to the forecasted $3.46. Despite maintaining its revenue projection of $58-61 billion for the year, Eli Lilly adjusted its full-year 2025 earnings forecast to a range of $20.78 to $22.28 per share, below the anticipated $22.40. CVS Caremark’s decision to make Novo Nordisk’s Wegovy its preferred weight-loss drug over Eli Lilly’s Zepbound also impacted the company, contributing to a significant drop in stock value. Analysts at Leerink Partners maintained an Outperform rating on Eli Lilly, viewing the stock dip as a buying opportunity and setting a price target of $944.00. Meanwhile, Eli Lilly continues to focus on its drug pipeline, with phase three data from several global trials for orforglipron anticipated by the end of 2025. Despite the challenges, the company remains committed to its strategic investments in manufacturing and R&D to drive future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.